Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Takafumi, Nishida"'
Autor:
Marcelo J. A. Amar, Lita A. Freeman, Takafumi Nishida, Maureen L. Sampson, Milton Pryor, Boris L. Vaisman, Edward B. Neufeld, Sotirios K. Karathanasis, Alan T. Remaley
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 1, Pp n/a-n/a (2020)
Abstract Familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD) is a rare genetic disease characterized by low HDL‐C levels, low plasma cholesterol esterification, and the formation of Lipoprotein‐X (Lp‐X), an abnormal cholestero
Externí odkaz:
https://doaj.org/article/a5400b9886c54798acd3bec096f0c038
Autor:
Makoto Ayaori, Hiroki Sato, Takafumi Nishida, Katsumi Hayashi, Tomohiro Komatsu, Katsumi Tamura, Kazuhiro Nakaya, Shunichi Takiguchi, Makoto Sasaki, Katsunori Ikewaki, Harumi Uto-Kondo, Emi Yakushiji
Publikováno v:
Journal of Atherosclerosis and Thrombosis. 29:775-784
Aims Inflammation is involved in various processes of atherosclerosis development. Serum C-reactive protein (CRP) levels, a predictor for cardiovascular risk, are reportedly reduced by statins. However, several studies have demonstrated that CRP is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e53881598c4538a6ba0215d7f3c4003c
https://doi.org/10.5551/jat.61630
https://doi.org/10.5551/jat.61630
Autor:
Takafumi Nishida, Makoto Ayaori, Junko Arakawa, Yumiko Suenaga, Kazusa Shiotani, Harumi Uto-Kondo, Tomohiro Komatsu, Kazuhiro Nakaya, Yasuhiro Endo, Makoto Sasaki, Katsunori Ikewaki
ObjectiveHigh density lipoprotein (HDL) exerts an anti-atherosclerotic effect via reverse cholesterol transport (RCT). Several phases of RCT are transcriptionally controlled by Liver X receptors (LXRs). Although macrophage LXRs reportedly promote RCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a991ad7f59d8350ed7df69f172a07b6b
https://doi.org/10.1101/2023.02.06.527401
https://doi.org/10.1101/2023.02.06.527401
Autor:
Tomohiro, Komatsu, Yuka, Katsurada, Kazuya, Miyashita, Satomi, Abe, Takafumi, Nishida, Yasuhiro, Endo, Manami, Teramoto, Kei, Sasaki, Junko, Arakawa, Makoto, Sasaki, Natsuko, Suzuki, Koji, Kuwata, Toshihiko, Imakiire, Takayuki, Miyake, Masami, Sakurada, Susumu, Matsukuma, Tsutomu, Hirano, Yoshinari, Uehara, Katsunori, Ikewaki
Publikováno v:
Journal of Atherosclerosis and Thrombosis.
Lecithin-cholesterol acyltransferase (LCAT) plays a significant role in the progression from premature to mature high-density lipoprotein (HDL) in circulation. Consequently, primary or secondary LCAT deletion or reduction naturally results in low ser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::853344235f7241097029506178bf9c55
https://doi.org/10.5551/jat.63616
https://doi.org/10.5551/jat.63616
Autor:
Tomohito Sato, Manabu Kinoshita, Tetsuo Yamamoto, Masataka Ito, Takafumi Nishida, Masaru Takeuchi, Daizoh Saitoh, Shuhji Seki, Yasuo Mukai
Publikováno v:
PLoS ONE, Vol 10, Iss 2, p e0117020 (2015)
Ascorbic acid is an effective antioxidant and free radical scavenger. Therefore, it is expected that ascorbic acid should act as a radioprotectant. We investigated the effects of post-radiation treatment with ascorbic acid on mouse survival. Mice rec
Externí odkaz:
https://doaj.org/article/3845345113ea44f9b1c4e174f6f58515
Autor:
Milton Pryor, Marcelo Amar, Alan T. Remaley, Takafumi Nishida, Sotirios K. Karathanasis, Maureen Sampson, Edward B. Neufeld, Boris L. Vaisman, Lita A. Freeman
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 1, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives
Familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD) is a rare genetic disease characterized by low HDL‐C levels, low plasma cholesterol esterification, and the formation of Lipoprotein‐X (Lp‐X), an abnormal cholesterol‐rich
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3949e5f43b134041568855fd93f6f9a0
https://doaj.org/article/a5400b9886c54798acd3bec096f0c038
https://doaj.org/article/a5400b9886c54798acd3bec096f0c038
Autor:
Shunichi Takiguchi, Harumi Uto-Kondo, Makiko Yogo, Katsunori Ikewaki, Emi Yakushiji, Maki Iizuka, Kazuhiro Nakaya, Takafumi Nishida, Tomohiro Komatsu, Masatsune Ogura, Yoshio Terao, Makoto Sasaki, Makoto Ayaori
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology
Supplemental Digital Content is available in the text.
Objective— Reverse cholesterol transport (RCT) is a major mechanism by which HDL (high-density lipoprotein) protects against atherosclerosis. Endothelial lipase (EL) reportedly reduces HDL
Objective— Reverse cholesterol transport (RCT) is a major mechanism by which HDL (high-density lipoprotein) protects against atherosclerosis. Endothelial lipase (EL) reportedly reduces HDL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92011c98c06911da2439557a6a3e119c
https://doi.org/10.1161/atvbaha.118.311056
https://doi.org/10.1161/atvbaha.118.311056
Autor:
Kazusa Shiotani, Katsunori Ikewaki, Makoto Sasaki, Makiko Yogo, Shunichi Takiguchi, Takafumi Nishida, Shinji Yokoyama, Tomohiro Komatsu, Rui Lu, Masatsune Ogura, Harumi Uto-Kondo, Emi Yakushiji, Kazuhiro Nakaya, Makoto Ayaori
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 36:591-597
Objective— Oxidized products of probucol, spiroquinone and diphenoquinone, were shown to increase cell cholesterol release and plasma high-density lipoprotein (HDL) by inhibiting degradation of ATP-binding cassette transporter A1. We investigated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df0e94cdc064d58803b69617bfe36cc7
https://doi.org/10.1161/atvbaha.115.306376
https://doi.org/10.1161/atvbaha.115.306376
Autor:
Takafumi Nishida, Robert D. Shamburek, Maureen Sampson, Edward B. Neufeld, Boris L. Vaisman, Lita A. Freeman, Alan T. Remaley, Toshihiro Sakurai, Akiko Sakurai, Stephen J. Demosky
Publikováno v:
Ann Clin Biochem
BackgroundLecithin:cholesterol acyltransferase (LCAT) is a plasma enzyme that esterifies cholesterol. Recombinant human LCAT (rhLCAT) is now being developed as an enzyme replacement therapy for familial LCAT deficiency and as a possible treatment for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4852c48c57e17289840d389322a004
https://pubmed.ncbi.nlm.nih.gov/28882064
https://pubmed.ncbi.nlm.nih.gov/28882064
Autor:
Takafumi Nishida, Harumi Uto-Kondo, Emi Yakushiji, Tomohiro Komatsu, Makoto Sasaki, Grace Megumi Sotherden, Yasuhiro Endo, Shunichi Takiguchi, Makoto Ayaori, Masatsune Ogura, Kazuhiro Nakaya, Makiko Yogo, Katsunori Ikewaki
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1841:1247-1255
Reverse cholesterol transport (RCT) is pivotal in the return of excess cholesterol from peripheral tissues to the liver for excretion in bile and eventually feces. RCT from macrophages is a critical anti-atherogenicity mechanism of HDL. As the choles
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d530f9541f73e0f443ab73f01185cc5
https://doi.org/10.1016/j.bbalip.2014.05.009
https://doi.org/10.1016/j.bbalip.2014.05.009